StockIQpro
NASDAQ:FBIO

Fortress Biotech, Inc.

Track all markets on TradingView
Track all markets on TradingView

Fortress Biotech, Inc.'s revenue grew 9.7% in fiscal 2025 to $63.3M while operating margin rose to −111.0%, its highest in 10 years. The diluted share count rose 34.2%.Summary generated from Fortress Biotech, Inc.'s SEC filings. Latest annual report filed Mar 31, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$63.3M
Revenue growth+9.7%
Revenue, 5-yr CAGR+6.8%
Gross margin66.9%
Operating margin−111.0%
Net margin10.8%
ROIC−239.4%
Return on equity18.8%
Debt / equity1.05
Free cash flown/a
FCF marginn/a
Share count change+34.2%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue6976855863
Operating income−189−204−142−110−70
Net income−65−87−61−467
Free cash flow−121−182−128−80n/a

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations